跳至主要内容
临床试验/JPRN-UMIN000012230
JPRN-UMIN000012230已完成1 期

Percutaneous cryoablation combined with transarterial embolization for treatment of renal cell carcinoma larger than 3 cm: Phase I/II clinical trial. - SCIRO-1301 study

Okayama University Hospital0 个研究点目标入组 19 人开始时间: 2013年11月7日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
19

研究概览

简要总结

19 patients (mean age, 75 years; 5 women, 14 men) were prospectively enrolled. Four grade 3 hematologic adverse events occurred, while no symptomatic grade????3 events occurred. The median follow up period was 68 (range 52 to 84) months. Two patients died from causes other than RCC. Overall survival, progression-free survival, and cause specific survival were 100%, 95%, and 100% at 3 years, and 95%, 84%, and 100% at 5 years, respectively.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • •1)Patients with extra-renal tumor spread 2)Patients with vascular invasion like venous tumor thrombus 3)There is a vital organ or major vessel along expected puncture line. 4)Patients have allergy for alcohol or contrast medium (iodine). 5)Patients have severe comorbidities as follows: a)Congestive heart failure failure (>= NYHA III) b)Active or uncontrolled clinically serious infection (excluding chronic hepatitis) 6)Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, excluding carcinoma in situ, cancers corresponding to intraepithelial or intramucosal neoplasia, any cancer curatively treated or, breast cancer/prostatic cancer in carcinostatic state. 7)Patients have a fever more than 38 C degree. 8)Patients is difficult to receive imaging evaluation like computed tomography (CT) or magnetic resonance imaging (MRI) 9)Female patients who are pregnant. 10)Any patients who is considered unsuitable for being enrolled in this clinical trial by a attending physician.

研究者

相似试验